Health Care/Hospital

VSure and HEYDOC Health Introduce CareConnect Suite, Transforming SME Protection and Digital Healthcare in Malaysia

KUALA LUMPUR, Malaysia, Dec. 9, 2025 /PRNewswire/ -- In a move that reflects the shifting expectations ofMalaysia's modern workforce, VSure Group and virtual healthcare provider HEYDOC Health have jointly launchedCareConnect Suite , a new digital ecosystem aimed at closing long-standing gaps in em...

2025-12-09 15:58 1744

Sweden Recommends: A Dose of Northern Lights Therapy

STOCKHOLM, Dec. 9, 2025 /PRNewswire/ -- As the world's first country to be prescribed for its health benefits,Sweden is now shining a light on one of its most awe-inducing wellness experiences. Aurora Borealis – the original arctic light therapy...

2025-12-09 15:53 1675

Greenyn Biotechnology Launches Insumate® mcIRBP-19 Bitter Melon Peptide, Targeting the Billion-Dollar Health Supplement Market

TAICHUNG, Dec. 9, 2025 /PRNewswire/ -- Backed by New Medical Association Certification, Insumate® Becomes the Only Bitter Melon Peptide Globally Recognized by FDA-NDI, SNQ, and the Taiwan Complementary Medicine Society (TCMS). As global demand for scientifically validated metabolic health ingred...

2025-12-09 10:30 2011

Therme Group acquires full Thermengruppe Josef Wund portfolio through Therme Horizon, integrating all four Wund-origin destinations into its global platform

MUNICH, Dec. 9, 2025 /PRNewswire/ -- Therme Group, a leading developer, owner and operator shaping the future of wellbeing infrastructure, today announced the acquisition of three thermal wellbeing destinations — Euskirchen, Sinsheim, and Titisee-Neustadt — from the Josef Wund Foundation. The tra...

2025-12-09 09:00 2609

CGTN: In the wake of tragedy, Hong Kong comes together to rebuild

BEIJING, Dec. 9, 2025 /PRNewswire/ -- CGTN published an article on the post-disaster rescue and reconstruction efforts following a devastating fire in Tai Po in the Hong Kong Special Administrative Region (HKSAR), highlighting the collective efforts by the central government and the HKSAR governme...

2025-12-09 08:54 2328

Inheritance + Innovation + Development: The "Co-development" Path of Hakka Medicine and Traditional Chinese Medicine

HONG KONG, Dec. 9, 2025 /PRNewswire/ -- From November 23 to 25, the Seventh World Hakka Entrepreneurs Convention was held in Meizhou,Guangdong. The conference, with the theme of "Gather Global Hakka Entrepreneurs • Facilitate High-Quality Development," upheld the principles of "openness, innovati...

2025-12-09 08:00 1907

With Child Deaths Projected to Rise for the First Time in a Century, Gates Foundation and Mohamed Bin Zayed Foundation for Humanity Urge Action as World Faces Critical Turning Point

 At Goalkeepers Abu Dhabi, global leaders outline a path to improve and save the lives of millions of children through lifesaving innovation and renewed investment Partners announce $1.9 billion to advance polio eradication Event held in partnership with the Mohamed bin Zayed Foundation for Huma...

2025-12-09 03:14 1612

EpiVax and FDA Scientists Publish New Insights on Immunogenicity Risks of Peptide-Related Impurities in Generic Teriparatide

PROVIDENCE, R.I., Dec. 9, 2025 /PRNewswire/ -- EpiVax, Inc. , with U.S. Food and Drug Administration (FDA) and CUBRC, Inc. (Buffalo, NY) scientist collaborators, announces the publ...

2025-12-09 03:11 1656

Menarini Group Presents Elacestrant (ORSERDU®) Phase 2 Combination Data in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2025 San Antonio Breast Cancer Symposium

* In addition, the expansive elacestrant clinical development program updates reinforce its potential as a backbone endocrine therapy in combination settings, as well as in both metastatic and early stage breast cancer. FLORENCE, Italy and NEW YORK, Dec. 8, 2025 /PRNewswire/ -- The Menarini Gro...

2025-12-09 03:05 2336

Halia Therapeutics Announces Positive Phase 2a Data for Ofirnoflast in Lower-Risk MDS at ASH 2025

– New findings demonstrate a 72% HI-E response rate at Week 16 with meaningful hemoglobin improvement – – Strong activity observed across ESA-refractory and ESA-intolerant patients, and across mutation and morphology subtypes – – Favorable safety profile with no treatment-related serious adverse e...

2025-12-08 22:22 1839

PT Fapon and PT Bio Farma Forge Strategic Partnership to Advance IVD Localization and Innovation in Indonesia

DONGGUAN, China, Dec. 8, 2025 /PRNewswire/ -- PT Fapon Bioindustries Indonesia (referred to as "PT Fapon") and the Indonesian state-owned pharmaceutical holding company PT Bio Farma (Persero) (referred to as "Bio Farma") officially signed a cooperation agreement at Fapon's headquarters inDongg...

2025-12-08 20:47 1848

Servier's Voranigo® (vorasidenib) Receives Prix Galien Awards Across Multiple Regions

* Voranigo® has been awarded the Prix Galien USA, the Prix Galien Poland and the Prix Galien Bridges Awards for Best Product for Orphan/Rare Diseases. * These awards across several geographies recognize the progress represented by Voranigo® for patients living with glioma. SURESNES, France, De...

2025-12-08 20:24 1793

Ascletis' Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted Weight Loss of 7.7% with Better Gastrointestinal Tolerability in Its 13-Week U.S. Phase II Study in Participants with Obesity or Overweight

-  ASC30 once-daily tablets showed statistically significant and clinically meaningful dose-dependent placebo-adjusted mean body weight reductions with no observed plateau for weight loss. -  ASC30 titrated weekly to target dose demonstrated approximately one-half the rate of vomiting observed w...

2025-12-08 17:40 3358

Qualcomm Highlights Edge AI Innovation at Qualcomm AI Program for Innovators (QAIPI) 2025 - APAC Demo Day and Sets the Stage for 2026

Showcasing transformative edge AI innovations across robotics, healthcare and smart city solutions SEOUL, South Korea, Dec. 8, 2025 /PRNewswire/ -- Qualcomm Technologies, Inc. hosted the Qualcomm AI Program for Innovators (QAIPI) 2025 – APAC Demo Day in Seoul, where 15 shortlisted startups from J...

2025-12-08 16:28 2408

UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder

* Seizure reduction: phase 3 study achieved primary endpoint as fenfluramine demonstrated a statistically significant reduction in countable motor seizure frequency (CMSF) compared with placebo1 * Holistic benefit: secondary endpoints showed significant and clinically meaningful improvements ...

2025-12-08 15:25 1231

Investment of Approx. USD 460,000 for the Development of a Prototype Mpox Detection Test with NIPRO, TBA, Japan Institute for Health Security and others

TOKYO, Dec. 8, 2025 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today an investment of approximatelyJPY 70 million (USD 460,0001) for the development of a prototype detection test for mpox (formerly known as monkeypox2). Mpox is a viral infectious disease that h...

2025-12-08 09:00 1586

RESPIREE SECURES SINGAPORE HSA APPROVAL FOR ITS AI-ENABLED 1BIO™AI SOFTWARE TO SUPPORT ACUTE DETERIORATION DETECTION

SINGAPORE, Dec. 8, 2025 /PRNewswire/ -- AI/ML health-tech startup Respiree has received approval from the Health Sciences Authority (HSA) for its 1Bio™AI-Acute toolbox as a Class B software-as-a-medical device (SaMD). The solution is designed to support healthcare pro...

2025-12-08 08:00 1781

AI-for-Science Startup ChemLex Raises USD 45M, Launching Self-Driving Lab for Drug Discovery in Singapore

SINGAPORE, Dec. 8, 2025 /PRNewswire/ -- ChemLex , a next-generation AI-for-science company, today announced the establishment of its global headquarters and self-driving laboratory inSingapore, alongside the close of aUSD 45 million funding round led by Granite Asia

2025-12-08 08:00 2205

ProstACT Global Phase 3 Update: First Patient Dosed in Randomized Treatment Expansion, Part 1 Readout Plans Confirmed

MELBOURNE, Australia and INDIANAPOLIS, Dec. 8, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patient has been dosed in Part 2 (randomized treatment expansion) of its ProstACT Global Phase 3 study evaluating its lead prostate can...

2025-12-08 06:08 1999

Leaders Dental Leads Korea's Prosthodontic Market With Large-Scale 300-Pyeong Production Infrastructure and a "Clinically Integrated Collaboration Model"

SEOUL, South Korea, Dec. 7, 2025 /PRNewswire/ -- Leaders Dental Laboratory, a major force driving the digitalization and large-scale transformation of Korea's dental laboratory industry, is solidifying its leadership with a production facility spanning over 300 pyeong. This extensive infrastructu...

2025-12-07 08:00 2319
1 ... 46474849505152 ... 541